for Thank everyone Steve, you, and thank joining us. you
capital growth. of cash to results further some We our are on from we runway. announced full to XXXX of in reported taking for sheet. touch our to top commercial items what cover financial line revenue I'm ground steps quarter expect our will have also balance to and XXXX and second updated lot highlight our trends year key a I we today jump half outline strengthen for the right related as second going we assay to outlook structure
Melanoma XXXX adoption unique sales as to Test operating us to in DermTech marketing market. post increase quarter in of The a be sample effective driving of sales volume of monthly daily second our year-over-year of XX% in growth reported We across elevated continued competitive a XX% metrics approximately ordering range marks our quarter sample a records XX% XX,XXX or X,XXX, volumes and despite way high multiple DMT. approximately and saw core team set the for turnover second clinicians the Along, and billable times. weekly we to XX% labor in rep to
We when operating resulted an sharpened which total extensive review and the flat in the through our focus budget compared operations expenses during few last essentially quarter. to also first months
considering our XX% cost call, laboratory last since Melanoma small reduced and investment per for per from team that, our the DMT contract potentially we We've results. earnings this for space. excellent efficient of other Test we per-unit adoption potential, in $XXX our and better in the sales more test second discipline DermTech team, to On commercial In a which in is required of were favor primary options. addition processes, producing initiative the noted care the understand paused Overall, the operating the quarter streamlined strong test the execution quarter. our by we to first $XXX in
entered we've care Quest, Arizona. in First, with primary an Sonora into distribution for agreement
day network patients more laboratory state. XX,XXX Quest testing Sonora throughout than in largest and the Arizona, is every serves the
primary pays testing will All the us key our commitment as these extending also Arrangements compared for care, force. such Our in they sample. direct our sales expanding reach capital lowering lab. while Quest our Diego as for to testing markets economics bills a such with good provide in a agreement samples, reference insurance per Sonora set establishes occur where fee a San model and generate
large part more or IDN traction, moving but slowly Midwest anticipated lingering the are impacts. to it's seeing and in established our related programs delivery in Florida COVID been Second, integrated steady network than both we
We care. use to primary different pilot IDN address care approach the types further also a we strategy believe our programs to of expand recently cases program off primary and targeted strategic payer/provider across market pilot of These commercial insights important to our right new an market can the with action. kicked is provide key course
last it of less average pressure selling commercial to favorable payers. Medicare few price from two are patterns primary collection for As areas; now impacts from relates We assay these or quarters. trends the believe we and ongoing emerging revenue, component ASP our seeing may a billing
tested insurance day. reject has claim edits where problematic been the multiple to processing Medicare that on sites due code Specifically, have body same claims patients
adopted also the have be eroding with engaged issue. improve NCCI to insurance payers edits contractor adopted in XXXX code billing the commercial second quarter fourth edits code new In will and that this ASP. further these of the Some Medicare's quarter, we expect
and We get over other higher. payments denied difficult systems payers billing months issues and to further in be their predict ASP also result expect factors identify adopt can to commercial impacts will coding moving change, that the but these how We'll these this the when it's exactly continue to monitor to we coming closely counteract updated.
to policy an US of for comes important covered channels and our payers lives in DermTech will Blues nearly a through engaged now ASP, to lives Texas. decisions Melanoma which and our progress factor Illinois of as largely today which are payers drive patients and and be total the and in California, commercial payers increasing and the activities Turning Advantage actively down for Test. Medicare million contract with million, variety where our XX physicians with XX we breaks for increasing remain approximately covered from million XX The Medicare advocacy
payer case. recent make that coverage payer. we due to bring dialogue. and remains indicators in payers Shifting gears and billable share the our volume with runway. is a goal developments, Carcinome, importantly and will sample current activity our good environment to on to pipeline recognized Luminate and confidence and of strong healthy increasing focus seeing to can't lot to undoubtedly data to our on footprint our details payers reinforce a we're will There's with These confident coverage given specifically, that of and a feedback investments we that payers our matter and with direct able evaluating time. unmet Overall, increases the reviews, pipeline product cash commercial our coverage non-contracted need the our contract that commercial from happening nationally we preserving budgets include indicators an belief of active a continue XXXX economic on the improve meaningfully and our advance bringing sample but projects be only that discussions. targeted volumes fulfills seeing make helps policy remain also sensitivity are that are additional happen, always The we We timelines
cancer clinical have Luminate, soon locked risk our the study. large complete and validation that samples a will that direct-to-consumer design skin assay For in offering multicenter were processing, we assesses collected
to Our is compelling a market opportunity. indicate continues research Luminate
our given the the growing to the of on the However, first half it we Luminate focus DMT prudent XXXX. environment, to of current for and push economic that introduction volumes is believe
test. the for continue of cell test presence carcinomas, As squamous as cell of the Carcinome and navigate a portion methodically such the to detect we basal challenges for development through cancers non-melanoma to the squamous skin
may this recall cell you cancers year. a for earlier we As classifier successfully basal identified
we intended to validate impact revenue and executing capital is candidates continue will up that headwinds our basal allocating have diligently crept remember were programs of a robust for we're these have XXXX never have disciplined trajectory. these believe mindful In way. cell to plan, to that recently working and a on product in commercial to studies. closing, short-term against well the on are to that a impact plans be classifier develop We an important we'll while utility addressing revenue It
success product to and pushing adoption the believe in in driving back. also is increase due in claims We denials insurance payers part our
sustained long-term more sample where ultimately review. We payer XXXX that, that forward commercial bring combined are with in our payer financial and our turn clear updating and that billable activities allocation activity in confident is Kevin on ASP priorities the robust commercial supporting for and are a growth. you drive to adoption volume over payers again detailed capital ahead. of traction call will months I earmarked. the With to I'll most look Growing
